Pertuzumab Trastuzumab Hyaluronidase

What is Pertuzumab Trastuzumab Hyaluronidase

Pertuzumab trastuzumab hyaluronidase is a combination product for subcutaneous use.

Both pertuzumab and trastuzumab are monoclonal antibodies and human epidermal growth factor receptor 2 (HER2)/neu-receptor antagonists; these drugs bind to different sites on HER2.

Hyaluronidase-zzxf is an endoglycosidase used to increase the dispersion and absorption of coadministered drugs when administered subcutaneously.

Pertuzumab trastuzumab hyaluronidase is indicated in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer or as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.

It is also indicated in combination with docetaxel for the treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

It has black box warnings for serious cardiotoxicity and pulmonary toxicity and a risk of embryo-fetal death and birth defects if used during pregnancy; use of effective contraception is necessary during and after therapy.

Indications

  • breast cancer

For the treatment of HER2-positive breast cancer

Side Effects

  1. abdominal pain
  2. abdominal pain
  3. acute respiratory distress syndrome (ARDS)
  4. alopecia
  5. anaphylactoid reactions
  6. anemia
  7. anemia
  8. angioedema
  9. anorexia
  10. anorexia
  11. antibody formation
  12. arthralgia
  13. asthenia
  14. asthenia
  15. atopic dermatitis
  16. back pain
  17. bone pain
  18. cardiomyopathy
  19. constipation
  20. cough
  21. cough
  22. diarrhea
  23. diarrhea
  24. dizziness
  25. dysgeusia
  26. dyspepsia
  27. dyspnea
  28. dyspnea
  29. elevated hepatic enzymes
  30. elevated hepatic enzymes
  31. epistaxis
  32. erythema
  33. fatigue
  34. fatigue
  35. fetal death
  36. fever
  37. headache
  38. heart failure
  39. hemorrhoids
  40. hot flashes
  41. hyperbilirubinemia
  42. hyperkalemia
  43. hyperkalemia
  44. hypernatremia
  45. hypernatremia
  46. hyperphosphatemia
  47. hyperuricemia
  48. hypoalbuminemia
  49. hypoglycemia
  50. hypokalemia
  51. hypokalemia
  52. hyponatremia
  53. hyponatremia
  54. infection
  55. infection
  56. influenza
  57. infusion-related reactions
  58. injection site reaction
  59. insomnia
  60. lacrimation
  61. lacrimation
  62. leukopenia
  63. leukopenia
  64. lymphopenia
  65. lymphopenia
  66. malaise
  67. muscle cramps
  68. musculoskeletal pain
  69. musculoskeletal pain
  70. myalgia
  71. myalgia
  72. nail discoloration
  73. nausea
  74. nausea
  75. nephrotoxicity
  76. neutropenia
  77. neutropenia
  78. palmar-plantar erythrodysesthesia (hand and foot syndrome)
  79. palmar-plantar erythrodysesthesia (hand and foot syndrome)
  80. paresthesias
  81. paresthesias
  82. peripheral edema
  83. peripheral neuropathy
  84. peripheral neuropathy
  85. pharyngitis
  86. pneumonitis
  87. pruritus
  88. pulmonary toxicity
  89. rash
  90. rash
  91. renal failure (unspecified)
  92. rhinorrhea
  93. stomatitis
  94. stomatitis
  95. teratogenesis
  96. thrombocytopenia
  97. tumor lysis syndrome (TLS)
  98. vomiting
  99. vomiting
  100. weight loss
  101. weight loss
  102. xerophthalmia
  103. xerophthalmia
  104. xerosis
  105. xerosis

Monitoring Parameters

  • ejection fraction
  • pregnancy testing
  • serum creatinine/BUN
  • serum electrolytes
  • serum uric acid

Contraindications

  • breast-feeding
  • cardiac arrhythmias
  • cardiac disease
  • cardiomyopathy
  • chronic lung disease (CLD)
  • contraception requirements
  • ensure correct formulation selection
  • geriatric
  • heart failure
  • hypertension
  • infusion-related reactions
  • intrauterine fetal death
  • myocardial infarction
  • pregnancy
  • pregnancy testing
  • pulmonary toxicity
  • reproductive risk
  • tumor lysis syndrome (TLS)
  • ventricular dysfunction

Interactions

No information is available regarding drug interactions associated with Pertuzumab Trastuzumab Hyaluronidase 

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856